Methods for the Diagnosis and Treatment of Neurological and Neurodegenerative Diseases, Disorders and Associated Processes
AssigneeC2N Diagnostics
InventorsTim West, Andrew C. Paoletti
Life of this patent
Estimating the term…
Abstract
Methods for the diagnosis, prognosis, treatment and determining the efficacy of a therapeutic regimen for neurological and neurodegenerative diseases, disorders, and associated processes include using a detectable label to measure levels of alpha-synuclein.
Claims25
A method to determine prognosis, diagnosis or efficacy of a therapeutic regimen in a subject comprising contacting a biological sample from a subject with a detectable isotope to detect the level of alpha-synuclein in the sample wherein the level is compared with a reference standard level [to determine the prognosis, diagnosis or efficacy of the therapeutic regimen.
A method to diagnose an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety to a subject suspected of having an alpha-synuclein related disease or disorder;
- (b) collection of a biological sample from the subject and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the subject to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in the alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of positive diagnosis of an alpha-synuclein related disease or disorder;
- thereby diagnosing an alpha-synuclein related disease or disorder.
A method to determine the prognosis of an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety to a subject suspected of having an alpha-synuclein related disease or disorder;
- (b) collection of a biological sample from the subject and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the subject to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in the alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of positive prognosis of an alpha-synuclein related disease or disorder;
- thereby prognosing an alpha-synuclein related disease or disorder.
A method to determine the efficacy of a therapeutic regimen to treat an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety and a therapeutic agent to a subject having an alpha-synuclein related disease or disorder;
- (b) collection of a biological sample from the subject and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the subject to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in the alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of efficacy of a therapeutic regimen of a therapeutic agent to treat an alpha-synuclein related disease or disorder;
- thereby determining the efficacy of a therapeutic regimen to treat an alpha-synuclein related disease or disorder.
An in vivo method to identify a therapeutic agent to treat an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety and a therapeutic agent to a subject suspected of having an alpha-synuclein related disease or disorder;
- (b) collection of a biological sample from the subject and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the subject to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of the identification of a therapeutic agent to treat an alpha-synuclein related disease or disorder;
- thereby identifying a therapeutic agent to treat an alpha-synuclein related disease or disorder an alpha-synuclein related disease or disorder.
An in vitro method to identify a therapeutic agent to treat an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety and a therapeutic agent to cells;
- (b) collection of alpha-synuclein from the cells and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the cells and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the cells and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the cells to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in alpha-synuclein metabolism of the cells compared to the corresponding normal sample is indicative of the identification of a therapeutic agent to treat an alpha-synuclein related disease or disorder;
- thereby identifying a therapeutic agent to treat an alpha-synuclein related disease or disorder an alpha-synuclein related disease or disorder.
A method to predict subject response to a therapeutic agent to treat an alpha-synuclein related disease or disorder comprising:
- (a) administration of a labeled moiety and a therapeutic agent to a subject suspected of having an alpha-synuclein related disease or disorder
- (b) collection of a biological sample from the subject and a corresponding normal sample;
- (c) measurement of labeled alpha-synuclein and unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (d) determination of the ratio of labeled alpha-synuclein to unlabeled alpha-synuclein from the subject and corresponding normal sample;
- (e) determination of alpha-synuclein metabolism from the ratios of step (d);
- and
- (f) comparison of the alpha-synuclein metabolism from the subject to the alpha-synuclein metabolism from the corresponding normal sample;
- wherein a change in the alpha-synuclein metabolism of the subject compared to the corresponding normal sample is indicative of the identification of a therapeutic agent to treat an alpha-synuclein related disease or disorder;
- thereby diagnosing an alpha-synuclein related disease or disorder.
A kit for determine prognosis, diagnosis or efficacy of a therapeutic regimen in a subject having or suspected of having an alpha-synuclein related disease or disorder.
Dependencies are inferred from the claim text.